NGAL/hepcidin-25 ratio and AKI subtypes in patients following cardiac surgery: a prospective observational study

Saban Elitok, Prasad Devarajan, Rinaldo Bellomo, Berend Isermann, Michael Haase, Anja Haase-Fielitz, Saban Elitok, Prasad Devarajan, Rinaldo Bellomo, Berend Isermann, Michael Haase, Anja Haase-Fielitz

Abstract

Background: Acute kidney injury (AKI) subtypes combining kidney functional parameters and injury biomarkers may have prognostic value. We aimed to determine whether neutrophil gelatinase-associated lipocalin (NGAL)/hepcidin-25 ratio (urinary concentrations of NGAL divided by that of hepcidin-25) defined subtypes are of prognostic relevance in cardiac surgery patients.

Methods: We studied 198 higher-risk cardiac surgery patients. We allocated patients to four groups: Kidney Disease Improving Global Outcomes (KDIGO)-AKI-negative and NGAL/hepcidin-25 ratio-negative (no AKI), KDIGO AKI-negative and NGAL/hepcidin-25 ratio-positive (subclinical AKI), KDIGO AKI-positive and NGAL/hepcidin-25 ratio-negative (clinical AKI), KDIGO AKI-positive and NGAL/hepcidin-25 ratio-positive (combined AKI). Outcomes included in-hospital mortality (primary) and long-term mortality (secondary).

Results: We identified 127 (61.6%) patients with no AKI, 13 (6.6%) with subclinical, 40 (20.2%) with clinical and 18 (9.1%) with combined AKI. Subclinical AKI patients had a 23-fold greater in-hospital mortality than no AKI patients. For combined AKI vs. no AKI or clinical AKI, findings were stronger (odds ratios (ORs): 126 and 39, respectively). After adjusting for EuroScore, volume of intraoperative packed red blood cells, and aortic cross-clamp time, subclinical and combined AKI remained associated with greater in-hospital mortality than no AKI and clinical AKI (adjusted ORs: 28.118, 95% CI 1.465-539.703; 3.737, 95% CI 1.746-7.998). Cox proportional hazard models found a significant association of biomarker-informed AKI subtypes with long-term survival compared with no AKI (adjusted ORs: pooled subclinical and clinical AKI: 1.885, 95% CI 1.003-3.542; combined AKI: 1.792, 95% CI 1.367-2.350).

Conclusions: In the presence or absence of KDIGO clinical criteria for AKI, the urinary NGAL/hepcidin-25-ratio appears to detect prognostically relevant AKI subtypes.

Trial registration number: NCT00672334, clinicaltrials.gov, date of registration: 6th May 2008, https://ichgcp.net/clinical-trials-registry/NCT00672334 . Definition of AKI subtypes: subclinical AKI (KDIGO negative AND Ratio-positive), clinical AKI (KDIGO positive AND Ratio-negative) and combined AKI (KDIGO positive AND Ratio-positive) with urinary NGAL/hepcidin-25 ratio-positive cut-off at 85% specificity for in-hospital death. AKI, acute kidney injury. AUC, area under the curve. NGAL, neutrophil gelatinase-associated lipocalin. KDIGO, Kidney Disease Improving Global Outcomes Initiative AKI definition.

Keywords: Cardiopulmonary bypass; Cardiorenal syndrome; NGAL/hepcidin-25 ratio; Subclinical AKI.

Conflict of interest statement

Saban Elitok: None. Prasad Devarajan: This author is a co-inventor on patents submitted for the use of NGAL as a biomarker of kidney injury. Rinaldo Bellomo: None. Berend Isermann: None. Anja Haase-Fielitz: None. Michael Haase: This author is a consultant to FastBiomedical and has received lecture honoraria and travel reimbursement from Siemens Healthcare Diagnostics, Abbott Diagnostics, Roche, Alere, Astute and Baxter on unrelated work.

© 2021. The Author(s).

Figures

Fig. 1
Fig. 1
In-hospital mortality grouped by AKI subtypes. Urinary NGAL/hepcidin-25 ratio after end of surgery (–), if ratio NGAL urine neutrophil gelatinase-associated lipocalin, KDIGO-AKI acute kidney injury according to the KDIGO criteria [2]
Fig. 2
Fig. 2
Long-term survival according to AKI subtypes. NGAL/hepcidin-25 ratio and allocated AKI subtype: log-rank test p < 0.001. Follow up time was 5.6 years. NGAL neutrophil gelatinase-associated lipocalin. Urinary NGAL and hepcidin-25 concentrations and NGAL/hepcidin-25 ratio immediately after end of surgery were available for all 198 patients. KDIGO-AKI acute kidney injury according to the KDIGO criteria [2]

References

    1. Wang Y, Bellomo R. Cardiac surgery-associated acute kidney injury: risk factors, pathophysiology and treatment. Nat Rev Nephrol. 2017;13:697–711. doi: 10.1038/nrneph.2017.119.
    1. Kellum JA, Lameire N, Aspelin P, et al. Kidney disease: improving global outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl. 2012;2:1–138. doi: 10.1038/kisup.2012.1.
    1. Thammathiwat T, Tiranathanagul K, Srisawat N, Susantitaphong P, Praditpornsilpa K, Eiam-Ong S. Clinical and subclinical acute kidney injury in multidrug-resistant septic patients treated with colistimethate sodium: Incidence and clinical outcomes. Nephrology (Carlton) 2020;25:32–39. doi: 10.1111/nep.13663.
    1. Dépret F, Hollinger A, Cariou A, et al. Incidence and outcome of subclinical acute kidney injury using penKid in critically Ill patients. Am J Respir Crit Care Med. 2020;202:822–829. doi: 10.1164/rccm.201910-1950OC.
    1. Albert C, Albert A, Kube J, et al. Urinary biomarkers may provide prognostic information for subclinical acute kidney injury after cardiac surgery. J Thorac Cardiovasc Surg. 2018;155:2441–2452. doi: 10.1016/j.jtcvs.2017.12.056.
    1. Akrawinthawong K, Ricci J, Cannon L, Dixon S, Kupfer K, Stivers D, Alexander P, David S, McCullough PA. Subclinical and clinical contrast-induced acute kidney injury: data from a novel blood marker for determining the risk of developing contrast-induced nephropathy (ENCINO), a prospective study. Ren Fail. 2015;37:187–191. doi: 10.3109/0886022X.2014.991994.
    1. Cho E, Kim SC, Kim MG, Jo SK, Cho WY, Kim HK. The incidence and risk factors of acute kidney injury after hepatobiliary surgery: a prospective observational study. BMC Nephrol. 2014;15:169. doi: 10.1186/1471-2369-15-169.
    1. Di Somma S, Magrini L, De Berardinis B, Marino R, Ferri E, Moscatelli P, Ballarino P, Carpinteri G, Noto P, Gliozzo B, Paladino L, Di Stasio E. Additive value of blood neutrophil gelatinase-associated lipocalin to clinical judgement in acute kidney injury diagnosis and mortality prediction in patients hospitalized from the emergency department. Crit Care. 2013;17:R29. doi: 10.1186/cc12510.
    1. Nickolas TL, Schmidt-Ott KM, Canetta P, et al. Diagnostic and prognostic stratification in the emergency department using urinary biomarkers of nephron damage: a multicenter prospective cohort study. J Am Coll Cardiol. 2012;59:246–255. doi: 10.1016/j.jacc.2011.10.854.
    1. Balla G, Jacob HS, Balla J, et al. Ferritin: a cytoprotective antioxidant strategem of endothelium. J Biol Chem. 1992;267:18148–18153. doi: 10.1016/S0021-9258(19)37165-0.
    1. Leaf DE, Rajapurkar M, Lele SS, et al. Iron, hepcidin, and death in human AKI. J Am Soc Nephrol. 2019;30:493–504. doi: 10.1681/ASN.2018100979.
    1. Albert C, Haase M, Albert A, et al. Urinary biomarkers may complement the Cleveland score for prediction of adverse kidney events after cardiac surgery: a pilot study. Ann Lab Med. 2020;40:131–141. doi: 10.3343/alm.2020.40.2.131.
    1. Haase M, Haase-Fielitz A, Plass M, et al. Prophylactic perioperative sodium bicarbonate to prevent acute kidney injury following open heart surgery: a multicenter double-blinded randomized controlled trial. PLoS Med. 2013;10:e1001426. doi: 10.1371/journal.pmed.1001426.
    1. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Int J Surg. 2014;12:1495–1499. doi: 10.1016/j.ijsu.2014.07.013.
    1. Nashef SA, Roques F, Michel P, Gauducheau E, Lemeshow S, Salamon R. European system for cardiac operative risk evaluation (EuroSCORE) Eur J Cardiothorac Surg. 1999;16:9–13. doi: 10.1016/s1010-7940(99)00134-7.
    1. Murray PT, Mehta RL, Shaw A, et al. ADQI 10 workgroup. Potential use of biomarkers in acute kidney injury: report and summary of recommendations from the 10th Acute Dialysis Quality Initiative consensus conference. Kidney Int. 2014;85:513–521. doi: 10.1038/ki.2013.374.
    1. Krawczeski CD, Goldstein SL, Woo JG, et al. Temporal relationship and predictive value of urinary acute kidney injury biomarkers after pediatric cardiopulmonary bypass. J Am Coll Cardiol. 2011;58:2301–2309. doi: 10.1016/j.jacc.2011.08.017.
    1. Haase M, Devarajan P, Haase-Fielitz A, et al. The outcome of neutrophil gelatinase-associated lipocalin-positive subclinical acute kidney injury: a multicenter pooled analysis of prospective studies. J Am Coll Cardiol. 2011;57:1752–1761. doi: 10.1016/j.jacc.2010.11.051.
    1. Moledina DG, Parikh CR. Phenotyping of acute kidney injury: beyond serum creatinine. Semin Nephrol. 2018;38:3–11. doi: 10.1016/j.semnephrol.2017.09.002.
    1. Sharma S, Leaf DE. Iron chelation as a potential therapeutic strategy for AKI prevention. J Am Soc Nephrol. 2019;30:2060–2071. doi: 10.1681/ASN.2019060595.
    1. van Swelm RP, Wetzels JF, Verweij VG, et al. Renal handling of circulating and renal-synthesized hepcidin and its protective effects against hemoglobin-mediated kidney injury. J Am Soc Nephrol. 2016;27:2720–2732. doi: 10.1681/ASN.2015040461.
    1. Kulaksiz H, Theilig F, Bachmann S, et al. The iron-regulatory peptide hormone hepcidin: expression and cellular localization in the mammalian kidney. J Endocrinol. 2005;184:361–370. doi: 10.1677/joe.1.05729.
    1. Russo E, Esposito P, Taramasso L, et al. Kidney disease and all-cause mortality in patients with COVID-19 hospitalized in Genoa, Northern Italy. J Nephrol. 2021;34:173–183. doi: 10.1007/s40620-020-00875-1.
    1. Meersch M, Schmidt C, Hoffmeier A, et al. Prevention of cardiac surgery-associated AKI by implementing the KDIGO guidelines in high risk patients identified by biomarkers: the PrevAKI randomized controlled trial. Intensive Care Med. 2017;43:1551–1561. doi: 10.1007/s00134-016-4670-3.
    1. Haase-Fielitz A, Elitok S, Schostak M, et al. The effects of intensive versus routine treatment in patients with acute kidney injury. Dtsch Arztebl Int. 2020;117:289–296. doi: 10.3238/arztebl.2020.0289.
    1. Thakar CV. Long-term outcomes of acute kidney injury: the power and pitfalls of observational/population-based studies. Am J Kidney Dis. 2017;69:3–4. doi: 10.1053/j.ajkd.2016.10.004.
    1. Zarbock A, Kellum JA, Schmidt C, et al. Effect of early vs delayed initiation of renal replacement therapy on mortality in critically ill patients with acute kidney injury: the ELAIN randomized clinical trial. JAMA. 2016;315:2190–2199. doi: 10.1001/jama.2016.5828.
    1. Parikh CR, Liu C, Mor MK, et al. Kidney biomarkers of injury and repair as predictors of contrast-associated AKI: a substudy of the PRESERVE trial. Am J Kidney Dis. 2020;75:187–194. doi: 10.1053/j.ajkd.2019.06.011.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren